Client insights Webinars

close

Choose a category.

• CEO Updates
• Core Offerings
• Leadership Events
• Media
• Observations
• Podcasts
• Special Reports
• Webinars

Blackstone Life Sciences combines deep scientific expertise with premier industry partnerships to provide product financing and equity solutions for late-stage clinical development, spanning pharmaceuticals, biotechnology, medical devices, diagnostics, and life science tools.

Heading into 2026, we maintain a constructive but increasingly selective outlook. A noisy backdrop of tariffs, trade disputes, snap elections and policy brinkmanship has so far proved largely surmountable for markets, with equities grinding higher and key assets such as oil looking through...

During the webinar, Laurence Marshbaum will discuss the new strategy, its composition and investment objectives. He will also talk to how The Fund will co-invest in Community Capital’s Social Purpose Organisation in Australia.

During the webinar, Laurence Marshbaum will discuss the new strategy, its composition and investment objectives. He will also talk to how The Fund will co-invest in Community Capital’s Social Purpose Organisation in Australia.

During the webinar, Laurence Marshbaum will discuss the new strategy, its composition and investment objectives. He will also talk to how The Fund will co-invest in Community Capital’s Social Purpose Organisation in Australia.

During the webinar, Laurence Marshbaum will discuss the new strategy, its composition and investment objectives. He will also talk to how The Fund will co-invest in Community Capital’s Social Purpose Organisation in Australia.

Investors are piling into the world’s most valuable stock, Nvidia, but adviser to the ultra rich LGT Crestone is taking a more cautious approach.

Investors are piling into the world’s most valuable stock, Nvidia, but adviser to the ultra rich LGT Crestone is taking a more cautious approach.

Investors are piling into the world’s most valuable stock, Nvidia, but adviser to the ultra rich LGT Crestone is taking a more cautious approach.